Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable ...

Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision ...

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc.

View Praxis Precision Medicines, Inc. PRAX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Praxis Precision Medicines Inc. PRAX said on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy ...

The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen ...

Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) on Wednesday, citing the potential of its epilepsy franchise. Analyst Rudy Li writes, “Epilepsy remains one of our ...

Shares in Praxis Medicines rose more than 28% today after the company said it was halting a trial of its experimental therapy for rare childhood epilepsies early and preparing to file for approval.

Shares in Praxis Precision Medicines were in freefall today after the company's efforts to develop a new therapy for major depressive disorder (MDD) ended in failure, forcing a restructuring and staff ...

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) pre ...